vinblastine / Generic mfg. - LARVOL DELTA

Preliminary Comparison of Competitive Efflux and Historical Transwell Assays for Assessing Canine P-Glycoprotein Substrate Status of Eleven Drugs Representing Ten Different Drug Classes. (PubMed, J Vet Pharmacol Ther) - "Eleven drugs were assessed as canine P-gp substrates by both methods, with two identified as non-P-gp substrates (erythromycin, propranolol) and nine identified as canine P-gp substrates (clarithromycin, daunorubicin, digoxin, etoposide, paclitaxel, quinidine, ritonavir, verapamil, vinblastine). Erythromycin was identified as a canine P-gp substrate by competitive efflux assay at roughly 10-fold higher concentrations than was used for transwell assays. Concordance of these methods assessing canine P-gp substrate status using historical data supports the need for head-to-head studies comparing these two methods for identifying canine P-gp substrates."

Journal • ABCB1

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.)."

Journal • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain • Transplantation

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. (PubMed, N Engl J Med) - P3 | "N+AVD resulted in longer progression-free survival than BV+AVD in adolescents and adults with stage III or IV advanced-stage classic Hodgkin's lymphoma and had a better side-effect profile. (Funded by the National Cancer Institute of the National Institutes of Health and others; S1826 ClinicalTrials.gov number, NCT03907488.)."

Clinical • Journal • Metastases • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pediatrics

Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. (PubMed, Eur Urol Oncol) - P3 | "We identified four factors prognostic for OS for patients with MIBC treated with NAC in VESPER. Basal molecular subtype was the most significant prognostic factor for OS, as it was independent of the treatment arm, and showed high prognostic value, in particular during the first year after randomization."

Biomarker • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Hidradenitis-Like Lesions as the Initial Presentation of Multisystem Langerhans Cell Histiocytosis With Liver, Lung, and Central Nervous System Involvement in an Adolescent: Diagnostic Pitfalls and Therapeutic Limitations (SOHO 2026) - "Case Presentation: A 17-year-old boy with hepatic steatosis, prediabetes, and recently diagnosed HS treated with zinc, metformin, and clindamycin, presented with extensive skin lesions...He started LCH-III therapy (vinblastine/prednisone) with improvement in many skin lesions... Severe "HS" with systemic symptoms can create diagnostic and therapeutic gridlock when the true driver is multisystem Langerhans cell histiocytosis (LCH), abruptly limiting HS options (eg, immunosuppression) and rendering surgery nonbeneficial. Early multidisciplinary coordination among dermatology, oncology, surgery, endocrinology, psychology, and social work enables timely biopsy/diagnosis, anticipates treatment constraints, and prioritizes symptom-directed HS care alongside cancer-directed therapy. This abstract was previously presented at Ochsner Research Week 2026, New Orleans, LA, May 21, 2026."

Hematological Malignancies • Oncology • AFP • CD1a

Variant Histology in Pediatric NLPBL: Adverse Biology Mitigated by R-CHOP, Including Feasible Early-Stage De-Escalation (SOHO 2026) - "Variant histology identifies a biologically and clinically higher-risk subgroup of pediatric NLPBL. However, this adverse impact appears to be mitigated by R-CHOP, with excellent outcomes—even in patients with variant histology. Our findings further suggest that risk-adapted de-escalation may be feasible in early-stage disease, including observation after complete resection and reduced-cycle R-CHOP for unresected stage 1–2 disease, without an apparent loss of efficacy."

Clinical • B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Nodular Lymphocyte Predominant Hodgkin Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. (PubMed, J Clin Oncol) - P3 | "In the VESPER trial, dd-MVAC improved 3-years PFS over GC. In the neoadjuvant group, a better bladder tumor local control and a significant improvement in 3-year PFS were observed in the dd-MVAC arm."

Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer

Preliminary outcomes of tovorafenib in children with BRAF-altered low-grade gliomas following prior therapy (EANO 2026) - "All patients had previously received antitumor therapy: vincristine/carboplatin chemotherapy (n=12), bevacizumab/vinblastine (n=7), and radiotherapy (n=2), as well as first-line targeted therapy with MEK inhibitor (n=15) or combined BRAF and MEK inhibition (n=2). Tovorafenib demonstrates clinical activity and a manageable safety profile in children with BRAF-altered LGG following prior targeted therapy. These findings are preliminary; further data maturation with longer follow-up and additional patients is ongoing."

Clinical • Brain Cancer • Glioma • Low Grade Glioma • Oncology • Pilocytic Astrocytoma • Solid Tumor • BRAF • KIAA1549

First-Line Treatment Patterns and Outcomes in Older Patients With Hodgkin Lymphoma in a Resource-Limited Setting: A Real-World Retrospective Single-Center Study (SOHO 2026) - "Five patients received the AEVD regimen (doxorubicin hydrochloride [Adriamycin], etoposide, vinblastine, and dacarbazine), of whom 3 were alive and disease-free at the time of analysis; outcome data for the remaining 2 patients were unavailable. This real-world experience suggests that bleomycin-sparing approaches, even without newer agents, are feasible in older patients with Hodgkin lymphoma and may offer a pragmatic treatment option in routine practice. In the absence of access to nivolumab or brentuximab vedotin, etoposide-based regimens could serve as a reasonable alternative. Larger prospective studies are warranted to better define optimal treatment strategies for this vulnerable population."

Real-world • Real-world evidence • Retrospective data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. (ASCO 2022) - P3 | "In ECHELON-1 (NCT01712490), 5-year follow-up analyses supported the long-term progression-free survival (PFS) benefit with first-line brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with stage III/IV cHL, independent of interim positron emission tomography status. A+AVD treatment resulted in a statistically significant 41% reduction in the risk of death vs ABVD, with a manageable safety profile consistent with prior reports. These outcomes confirm A+AVD as a preferred option for pts with previously untreated stage III/IV cHL."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain

Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. (PubMed, J Clin Oncol) - "Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment in localized Hodgkin Lymphoma H10 Trial demonstrated that in ePET-negative patients, the risk of relapse increased when involved-node radiotherapy (INRT) was omitted and that in ePET-positive patients, switching from doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) to bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPPesc) significantly improved 5-year progression-free survival (PFS). In conclusion, the present long-term analysis confirms that in ePET-negative patients, the omission of INRT is associated with lower 10-year PFS. Instead, in ePET-positive patients, no significant difference between standard and experimental arms emerged..."

Journal • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Pembrolizumab and Involved Site Radiation Therapy Alone as an Alternative to Transplant in Patients with Localized Failure following Chemotherapy for Hodgkin Lymphoma: A Prospective Multicenter Phase II Study (ASTRO 2025) - "16 (89%) received doxorubicin/hydroxydaunorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), 12 (67%) with <6 cycles...Subsequent treatment for the three patients currently in remission included pembro plus gemcitabine/vinorelbine/liposomal doxorubicin followed by ASCT (n=1), brentuximab vedotin (BV) plus nivolumab followed by ASCT (n=1) and 2 doses of BV followed by additional RT (n=1)... Pembro-RT yielded excellent CMR rates and minimal toxicity. These data suggest pembro-RT as a potential alternative to high dose chemo and SCT in localized, favorable relapsed/refractory HL. Enrollment to the study is complete and data will be updated prior to the meeting."

Clinical • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

2-YEAR FOLLOW-UP OF THE S1826 STUDY CONFIRMS IMPROVED PROGRESSION-FREE SURVIVAL WITH NIVOLUMAB-AVD COMPARED TO BRENTUXIMAB VEDOTIN-AVD IN ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA (ISHL 2024) - "We hypothesized that introducing PD-1 blockade with nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (N-AVD) would improve progression-free survival (PFS) over BV-AVD in AS cHL and evaluated this approach in the randomized, phase 3 S1826 study. N-AVD was better tolerated and improved PFS versus BV-AVD in adolescent and adult pts with AS cHL. Longer follow-up confirmed the PFS benefit with N-AVD at 2 y, including pre-specified subgroups. N-AVD is a new standard of care for treatment of AS cHL."

Metastases • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Immunology • Infectious Disease • Lymphoma • Musculoskeletal Pain • Neutropenia • Oncology • Pain • Pediatrics • Pneumonia

Nivolumab+AVD vs eBEACOPP in Advanced-Stage Classic Hodgkin Lymphoma: Single-Center, Nonrandomized, Prospective Clinical Trial (Real Clinical Practice) (SOHO 2026) - "N-AVD resulted in longer progression-free survival than eBEACOPP in adults with advanced-stage cHL and had a better side-effect profile. eBEACOPP: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone in escalated doses, ECOG: Eastern Cooperative Oncology Group, HR: hazard ratio, N-AVD: nivolumab plus doxorubicin, vinblastine, and dacarbazine, PET-CT: positron emission tomography-computed tomography."

Clinical • Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Clinical Outcomes of PD-1/PD-L1 Inhibitors in Hematologic Malignancies: A Systematic Review Across Lymphoma, Leukemia, and Multiple Myeloma (SOHO 2026) - "Studies evaluating PD-1/PD-L1 inhibitors, including nivolumab, pembrolizumab, durvalumab, and atezolizumab, in lymphoma, leukemia, and MM were reviewed...In frontline advanced-stage cHL, nivolumab combined with AVD demonstrated improved PFS compared with brentuximab vedotin plus AVDin the SWOGS1826 trial... PD-1/PD-L1 inhibitors have significantly improved outcomes in cHL and continue to show potential in selected NHL subtypes. In contrast, their role in MM remains limited because of safety concerns and reduced efficacy, while data in leukemia are still evolving. Further studies are needed to better define the role of checkpoint inhibitors and combination immunotherapy strategies across different hematologic malignancies."

Clinical • Clinical data • Review • B Cell Lymphoma • Classical Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Mediastinal B Cell Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma

Neoadjuvant Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer: A Phase 2 Trial. (PubMed, Eur Urol) - "These findings suggest that chemoimmunotherapy is a very promising approach for MIBC with histology subtypes. Larger studies are warranted to further refine therapeutic strategies."

IO biomarker • Journal • P2 data • Bladder Cancer • Genito-urinary Cancer • Oncology • Sarcoma • Solid Tumor

Long-Term Follow-Up Results of aMVAC Arm of ECOG-ACRIN EA8141: a Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High-Grade Upper Tract Urothelial Carcinoma (AUA 2026) - P2, P2/3 | "ECOG-ACRIN EA8141 investigated the role of 4 cycles of aMVAC (accelerated methotrexate, vinblastine, doxorubicin, and cisplatin) NAC in patients with HG-UTUC and cisplatin eligible, or gemcitabine and carboplatin (GCa) for 30≤CrCl≤50 ml/min for those who were cisplatin ineligible. NAC with aMVAC demonstrated a durable long-term benefit in patients with HG UTUC and CrCl>50 ml/min. The results of EA8141 have contributed to a change in AUA guidelines, which now endorse use of NAC in HG UTUC. Long-term results continue to support a clinical benefit of neoadjuvant aMVAC in eligible HG UTUC patients."

Clinical • P2 data • Surgery • Bladder Cancer • Oncology • Solid Tumor • Urothelial Cancer

Safety and Efficacy of ABVD Protocol in Pregnant Patients With Classic Hodgkin Lymphoma: A Single-Center Experience (SOHO 2026) - "All patients received doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with or without involved-field radiotherapy. Therapeutic strategies were tailored, integrating symptomatic burden of disease, gestational age, and patient preferences to optimize the balance between maternal disease control and fetal outcomes. This cohort supports the safety profile of ABVD during pregnancy, including cases of advanced-stage cHL, while highlighting the critical necessity of multidisciplinary team involvement, shared decision-making, and comprehensive patient counseling."

Clinical • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study. (PubMed, Scand J Urol) - P=N/A | "This study reports current RC practices amongst Nordic countries. Patient cohorts did not differ between countries, and although the practices were generally similar, some differences were noted in chemotherapy regimens, the use of robotic-assisted surgery and rates of early RC."

Clinical • Journal • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor

Brentuximab Vedotin With Adriamycin, Vinblastine, and Dacarbazine for Patients Aged 18-59 Years With Untreated Advanced Stage Classical Hodgkin Lymphoma: The Largest Real-Life Series From Southern Italy Cancer Centers. (PubMed, Eur J Haematol) - P | "BV + AVD is increasingly used for frontline treatment of stage III/IV cHL. In Ya&A with high-risk cHL, our data suggest that a BV-driven strategy (without bleomycin and consolidation radiotherapy) is an effective up-front option in oncologic centers specialized in HL care, improving the rate of durable complete remission in routine clinical practice. Trial Registration: ClinicalTrials.gov identifier: NCT06857500."

Journal • Cardiovascular • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology • Pain

Less Is More: Complete Metabolic Response With Low-Dose Nivolumab as Bleomycin Replacement for Stage 4 Classical Hodgkin Lymphoma (SOHO 2026) - "Brentuximab vedotin and standard-dose nivolumab (200 mg)—now preferred frontline substitutes—remain financially inaccessible in resource-limited settings. To our knowledge, this is the first reported case of low-dose nivolumab as a bleomycin substitute driven simultaneously by toxicity and affordability, a dual indication unrepresented in existing trials, warranting prospective validation. ABVD: doxorubicin, bleomycin, vinblastine, dacarbazine; AVD: doxorubicin, vinblastine, dacarbazine; cHL: classical Hodgkin lymphoma; CKD: chronic kidney disease; CR: complete response; ORR: objective response rate; PET-CT: positron emission tomography and computed tomography; PD-1: programmed cell death protein."

Metastases • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Brentuximab Vedotin and Nivolumab in Combination With Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma. (PubMed, Blood) - P2 | "Most patients with early-stage classical Hodgkin lymphoma (cHL) are treated with doxorubicin, bleomycin, vinblastine, and dacarbazine with or without radiation therapy, although studies are now evaluating the incorporation of novel agents paired with abbreviated chemotherapy. Results from this study support the use of BV and nivolumab in combination with limited chemotherapy in patients with non-bulky, early-stage cHL. ClinicalTrials.gov: NCT03646123."

Journal • Classical Hodgkin Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Neutropenia • Oncology

EORTC-1537-COBRA: PHASE II STUDY OF VERY EARLY FDG-PET-RESPONSE ADAPTED TARGETED THERAPY FOR ADVANCED HODGKIN LYMPHOMA. PRIMARY ANALYSIS INCLUDING VALUE OF QUANTITATIVE PET ASSESSMENT AND TARC DYNAMICS (ISHL 2024) - "In cHL patients <60 years treated in the experimental arm of the ECHELON-1 study all patients received 6 x A-AVD (brentuximab vedotin, doxorubicin, vinblastine, dacarbazine) regardless of early PET results...The COBRA trial investigated early PET-response adapted treatment in BV-based first line therapy, by intensification to BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) in patients PETpositive after 1 cycle of A-AVD. The primary endpoint of this phase II study was modified progression-free survival rate at 2 years from start of treatment (2 y mPFS)... Treatment adaptation based on a very early FDG-PET/CT leads to very high efficacy in advanced stage HL patients receiving BV-containing first-line treatment while sparing most patients intensive chemotherapy. Semiquantitative assessment of interim PET and/or TARC analysis enhances the positive predictive value of the early response assessment and can potentially..."

FDG PET • Metastases • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Novel production of vinblastine by immobilized cultures of mutant strain of the endophytic Alternaria alternata. (PubMed, World J Microbiol Biotechnol) - "Repeated-batch cultivation confirmed the reusability of immobilized beads, with the first two cycles maintaining high vinblastine titers of 7.00 ± 0.24 and 6.81 ± 0.36 mg L⁻¹. Overall, this study establishes alginate-immobilized A. alternata Mut-85 as an efficient and reusable platform for enhanced fungal vinblastine production."

Journal • Oncology

Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma. (ASCO 2024) - P3 | "Background: In ECHELON-1 (NCT01712490), 6-year follow-up (FU) analyses demonstrated significant improvements in overall survival (OS) and progression-free survival (PFS) with A+AVD (brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), with a comparable safety profile. At 7-year median FU, pts with stage III/IV cHL who received A+AVD showed a sustained PFS and OS benefit vs ABVD, with PFS rates indicating potential curability. The safety profile in pts treated with A+AVD showed no new safety signals at 7 years."

Clinical • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology • Pain